To download the redacted AAO Industry Insights Report please complete the form below:
AAO 2019 marked a pivotal moment in the retinal space. Data were presented to accompany the long-awaited launch of brolucizumab, while important interim data supporting abicipar, risuteganib, ranibizumab PDS, faricimab, and aflibercept were shared with all the attending delegates.
During AAO, iOPEN conducted a pilot program utilizing the power of the QROWD (Quick Responses of Worldwide Doctors) to obtain validated and targeted customer opinions on key data presented during the congress. Our QROWD experts comprise a representative group of target clinicians from differing locations and with differing levels of experience. For AAO, this team of top-tier, mid-tier, and ground-level experts provided instant, independent answers to key questions on the presented data. The responses were collated and analyzed by our three core faculty members.
The US retina market is now more complex than ever, and constantly evolving competitor landscapes mean the evidence base and commercial positioning you need today may be considered outdated and redundant by tomorrow. This is where the iOPEN AAO Industry Insights Report can help.
The comprehensive iOPEN AAO Industry Insights Report uniquely offers top-level insights on the pivotal presented AAO data from our world-renowned core iOPEN faculty; Tarek Hassan, Carl Awh, and David Chow; together with honest crowdsourced opinions independently collated from a wide cross-section of retina specialists using our landmark proprietary QROWD platform.
Please complete this form to download the redacted AAO Industry Insights Report
The iOPEN AAO Industry Insights Report can help you discover what retina specialists really think about the data you and your competitors presented at AAO. Together with the summaries provided by our expert faculty, you can also find out WHY retina specialists hold these opinions. We can help you answer questions such as: